Tom E. Stinchcombe, MD, on NSCLC: Strategies for Managing Secondary Primary Disease

October 02, 2023 By The ASCO Post Staff

Tom E. Stinchcombe, MD, of Duke Cancer Institute, discusses an analysis of the rate of second primary lung cancer from the CALGB (Alliance) 140503 trial of lobar vs sublobar resection for T1a N0 non–small cell lung cancer (NSCLC). The data have implications for surveillance and screening strategies for patients with resected stage I disease (Abstract OA12.03).

Related Content